(Q46586074)

23 December 2017

title

Ropinirole in treatment-resistant depression: a 16-week pilot study (English)

1 reference

23 December 2017

treatment-resistant depression

main subject

1 reference

Paolo Cassano

1

1 reference

23 December 2017

Lorenzo Lattanzi

2

1 reference

23 December 2017

Maurizio Fava

3

1 reference

23 December 2017

Serena Navari

4

1 reference

23 December 2017

Giulia Battistini

5

1 reference

23 December 2017

Marianna Abelli

6

1 reference

23 December 2017

Giovanni B Cassano

7

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

23 December 2017

Canadian Journal of Psychiatry

published in

1 reference

23 December 2017

volume

50

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

357-360

1 reference

23 December 2017

Clinical pharmacokinetics of ropinirole

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Pramipexole for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Definition and epidemiology of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson???s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370505000612

10.1177/070674370505000612

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017